Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity
Chemotherapy of prostate cancer with antimitotic agents such as vinblastine and doxorubicin is only marginally effective, due to dose-limiting systemic toxicity. Herein we report the development of peptidyl conjugate 5 of the cytotoxic agent vinblastine (
Brady, Stephen F.,Pawluczyk, Joseph M.,Lumma, Patricia K.,Feng, Dong-Mei,Wai, Jenny M.,Jones, Raymond,DeFeo-Jones, Deborah,Wong, Bradley K.,Miller-Stein, Cynthia,Lin, Jiunn H.,Oliff, Allen,Freidinger, Roger M.,Garsky, Victor M.